Full-Time

Director – Analytics and Insights Lead

Regulatory Affairs Resource

Gilead Sciences

Gilead Sciences

10,001+ employees

Biopharmaceutical firm developing HIV/AIDS therapies

Compensation Overview

$191.3k - $272.3k/yr

+ Discretionary Annual Bonus + Discretionary Stock-based Long-term Incentives

No H1B Sponsorship

San Mateo, CA, USA + 1 more

More locations: Parsippany-Troy Hills, NJ, USA

In Person

On-site required in Parsippany, NJ and Foster City, CA.

US Top Secret Clearance Required

Bachelor's, Master's, PhD

Category
Legal & Compliance (1)
Required Skills
Forecasting

Get referred to Gilead Sciences

See people who can refer or advise you

Requirements
  • MA / MS / MPH with 10+ years of Regulatory Affairs, resource and/or project management OR 8+ years with a PhD with relevant experience OR a BA / BS with 12+ years Regulatory Affairs, resource and/or project management.
  • Experience managing complex projects and implementations.
  • Planisware, Smartsheet (including Resource Manager, Control Center), or other named resourcing experience required.
  • Knowledge of resourcing and forecasting methods and applicable tools for tracking and forecasting needs.
  • Strong understanding of the research and drug development life cycle processes, roles and systems required.
  • Ability to influence and drive decisions without direct authority.
  • Demonstrated negotiation, problem solving, critical thinking and facilitation skills.
  • Strong quantitative reasoning and analytical ability.
  • History of motivating others with a positive attitude to deliver to important milestones while maintaining a positive, transparent, and collaborative team environment.
  • Ability to establish priorities, operate with a sense of urgency and collaborate (interpersonal, relationship management) with cross functional team members.
  • Ability to proactively gather, interpret and evaluate information from a variety of resources to make decisions and recommendations.
  • Proven ability to multitask in order of priority in a deadline driven environment with optimal efficiency and accuracy.
  • Ability to communicate in a clear and concise manner.
  • Ability to support a team-oriented, highly matrixed environment.
  • Ability to execute multiple tasks as assigned.
  • When needed, ability to travel.
  • People Leader Accountabilities: Create Inclusion - knowing the business value of diverse teams, modeling inclusion, and embedding the value of diversity in the way they manage their teams.
  • People Leader Accountabilities: Develop Talent - understand the skills, experience, aspirations and potential of their employees and coach them on current performance and future potential. They ensure employees are receiving the feedback and insight needed to grow, develop and realize their purpose.
  • People Leader Accountabilities: Empower Teams - connect the team to the organization by aligning goals, purpose, and organizational objectives, and holding them to account. They provide the support needed to remove barriers and connect their team to the broader ecosystem
Responsibilities
  • Own the data quality, infrastructure, and business practices related to resource management.
  • Leads special projects and pilots that advance the capabilities of RA Business Operations.
  • Provide support across Business Operations capabilities as needed (Vendor Management, Business Process Excellence, Inspection Readiness, Business Process Excellence, Change Management, Communications and Engagement)
  • Makes significant contributions to short- and long-range RA strategies, plans, and infrastructure development, and Development, RSQ and RA-wide initiatives and evolutions.
  • Collaborate within Human Capital (Resource Management and Vendor Management) to drive holistic internal/external resourcing strategies across RA
  • Embed resource management concepts and influence the culture and practices across RA as it pertains to managing demand, increasing capacity, developing talent in line with strategy, and creative solutioning.
  • Build relationships and trust with a network of leaders and sub-functional spoke contacts to influence and deliver the goals of resource management and Business Operations
  • Manage difficult conversations including headcount discussions, prioritization, and interrogation of data quality
  • Lead yearly Strategic Workforce Planning cycles in partnership with Head of Human Capital. Track and drive changes to address gaps identified in workforce.
  • Oversee the maintenance of algorithmic forecasting (Planisware) in collaboration with others on the Human Capital team to improve algorithm accuracy and leadership understanding of resource trends.
  • Orchestrate across RA leadership, Finance (LE cycles) and HR to enable the workforce needed to drive our portfolio.
  • Aligns resource data and planning efforts to facilitate decision-making forums, including capacity planning and initiative review meetings.
  • Provides guidance and recommendations, based on data, of the future resource needs for latest estimate/year end processes, etc. for Regulatory Affairs functional areas as needed. This role is the consultant to the business on all things resourcing related.
  • Partners with the Regulatory Affairs Leadership Team to develop mitigation plans to address gaps in demand and capacity in collaboration with the Human Capital Lead and Vendor Governance.
  • Provides formal and informal training of resource concepts, processes, tools, and reports.
  • Oversee technical administration of Planisware and Smartsheet Resource Manager tools in collaboration with Human Capital team members and Performance Excellence Infrastructure Lead
  • Continual improvement and maturation of Resource Management capability
  • Develop performance and resource management guidelines and training materials for team leads and project managers.

Gilead Sciences discovers, develops, and markets medicines to treat HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Its products reach patients globally after regulatory approval, sold through doctors, hospitals, and pharmacies. The company relies on a large, diverse R&D pipeline and strategic partnerships to expand its therapies and reach, including collaborations like SAP Ariba to improve sourcing. Its goal is to improve health equity by expanding access to medicines and promoting sustainable healthcare practices worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 product sales rose 10% to $7.6 billion; HIV grew 12%.
  • Yeztugo generated $232 million in Q2 2026 and targets roughly $1 billion annually.
  • California Supreme Court rejected the duty-to-innovate theory on August 3, 2026, removing massive liability.

What critics are saying

  • Biktarvy still drives enormous revenue; any 2036 generic shock would hit earnings hard.
  • California TDF lawsuits targeted 24,000 patients; future claims still threaten legacy HIV cash flows.
  • Merck and ViiV are compressing Gilead's moat with weekly oral and injectable HIV rivals.

What makes Gilead Sciences unique

  • Biktarvy kept 70% of HIV franchise revenue in 2025, reinforcing entrenched switching costs.
  • Lenacapavir powers Yeztugo and weekly ISL/LEN, giving Gilead unmatched long-acting HIV breadth.
  • August 2026 oncological ADC work with Nucleai deepens biomarker-driven development across oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 13th, 2026
Gilead Sciences beats Q2 estimates with $7.8B revenue as PrEP sales top $1B for first time

Gilead Sciences reported strong Q2 results, with revenue of $7.80 billion, beating analyst estimates of $7.35 billion. The 10.2% year-on-year growth was driven by its HIV franchise, particularly Biktarvy and the PrEP segment, alongside advances in oncology and liver disease treatments. CEO Daniel O'Day highlighted that quarterly PrEP sales doubled year-on-year, exceeding $1 billion for the first time. New product launches, including Trodelvy in breast cancer and Livdelzi in liver disease, contributed to the results. The company raised its full-year revenue guidance to $30.25 billion at the midpoint and increased adjusted EPS guidance by 44.1%. During the earnings call, analysts questioned management about prescription trends, product strategies, revenue diversification, regulatory interactions, and the impact of US insurance changes on Biktarvy's growth.

Ochre Digi Media Pvt. Ltd.
Aug 12th, 2026
Nucleai advances ai-powered Tissue Intelligence through large-scale oncology ADC collaboration.

Nucleai advances ai-powered Tissue Intelligence through large-scale oncology ADC collaboration. Wednesday, August 12, 2026 Nucleai, a leader in AI-powered Tissue Intelligence, which integrates multimodal tissue image analysis with clinical data to deliver translational insights, today announced an ongoing translational research collaboration with Gilead Sciences supporting its global antibody-drug conjugate (ADC) clinical development programs. As oncology drug development increasingly depends on understanding tissue biology in its spatial context, AI-powered tissue analytics are becoming an essential component of biomarker discovery and translational research. Pharmaceutical companies are increasingly adopting approaches that integrate tissue architecture, biomarker expression, and clinical outcomes to accelerate therapeutic development. Nucleai's AI-native platform transforms routine pathology images into quantitative biological insights that accelerate biomarker discovery and support evidence-driven development decisions. As part of its collaboration with Gilead, Nucleai has analyzed a large dataset of hematoxylin and eosin (H&E) and immunohistochemistry (IHC) whole-slide images across several clinical studies spanning multiple oncology indications, supporting Gilead's global ADC clinical development programs through advanced AI-driven tissue analytics integrated with clinical outcomes. The collaboration has generated novel biological insights and candidate spatial biomarkers for future scientific presentations and publications. The collaboration demonstrates how AI-powered Tissue Intelligence can standardize biomarker analyses while connecting tissue biology to clinical outcomes, creating a scalable foundation for translational research, biomarker development, and precision medicine. "Precision oncology is entering a new phase, where understanding tissue architecture is becoming just as important as understanding molecular alterations," said Avi Veidman, Chief Executive Officer of Nucleai. "Tissue Intelligence is becoming a foundational capability for precision medicine, helping identify the patients most likely to benefit while enabling pharmaceutical companies to translate tissue biology into reproducible biomarkers that improve the speed and success of oncology drug development." Unlike traditional image analysis approaches, Nucleai's AI-native platform integrates computational pathology, spatial biology, clinical outcomes, and multimodal data into a unified framework. This enables standardized biomarker assessment from preclinical research through late-stage clinical development while revealing mechanisms of response, resistance, and disease progression. The ongoing collaboration with Gilead and other leading pharmaceutical companies reflects growing industry recognition that AI-powered tissue analytics strengthen biomarker development and precision medicine across oncology portfolios. As target expression alone proves insufficient to explain ADC response, Nucleai's Tissue Intelligence platform integrates protein expression with tissue architecture, tumor heterogeneity, and microenvironmental context to better characterize the biological drivers of therapeutic efficacy. "Scale and reproducibility are becoming essential requirements for biomarker development," said Dr. Ken Bloom, Head of Pathology, Nucleai. "Our platform enables standardized spatial analyses across thousands of clinical samples while directly linking tissue biology to patient outcomes, generating evidence that can support translational research, biomarker qualification, and future companion diagnostic strategies." Nucleai continues to expand collaborations with leading pharmaceutical companies to advance biomarker discovery, translational medicine, companion diagnostic development, and AI-powered Tissue Intelligence across the oncology development lifecycle. About Nucleai Nucleai is a leader in AI-powered Tissue Intelligence, transforming pathology images into clinically actionable insights for pharmaceutical companies developing the next generation of precision medicines. By integrating computational pathology, spatial biology, multi-omics, and clinical data, Nucleai enables biomarker discovery, translational research, companion diagnostic development, and enterprise-scale AI-powered tissue analytics across the oncology development lifecycle. Contacts Media Contact Patrick Schmidt, Consort Partners [email protected]

Yahoo Finance
Aug 8th, 2026
Gilead raises 2026 outlook on HIV and PrEP strength, targets $30B in sales

Gilead Sciences reported second-quarter 2026 results that exceeded expectations, with revenues of $7.8 billion, up 10% year over year, and a non-GAAP loss per share of $6.75 beating consensus estimates. The company raised its full-year guidance for product sales excluding Veklury to $29.8 billion to $30.1 billion, an increase of $350 million at the midpoint. HIV sales drove growth, rising 12% in the quarter. Quarterly PrEP sales surpassed $1 billion for the first time, putting the prevention business at a $4 billion annual run rate. Gilead now expects full-year HIV sales to increase 9% to 10%, up from its prior 8% outlook. Biktarvy generated $3.8 billion in sales, whilst newer product Yeztugo delivered $232 million. The company maintained its approximately $1 billion full-year Yeztugo sales target, with more than 70% of users returning for reinjection at six months.

Yahoo Finance
Aug 4th, 2026
Gilead Q2 sales rise 8% to $7.8B, beating estimates despite acquisition-related loss

Gilead Sciences reported second-quarter product sales rose 8%, driven by double-digit growth in HIV drugs. Overall revenue increased 10% to $7.8 billion, surpassing Wall Street's $7.4 billion estimate. HIV sales grew 12%, whilst cancer drug Trodelvy and liver disease drug Livdelzi also performed strongly. HIV prevention drug Yeztugo generated $232 million, exceeding forecasts, whilst Descovy sales jumped 48% to $967 million. The company posted a quarterly loss due to acquisition costs. Gilead narrowed its projected full-year loss and slightly raised its revenue outlook to between $30.1 billion and $30.4 billion. The California-based biotech firm expressed confidence in achieving $1 billion in annual Yeztugo sales.

Yahoo Finance
Aug 3rd, 2026
California Supreme Court rules for Gilead, rejects 'duty to innovate' in case with 24,000 HIV patients

California's Supreme Court ruled 6-1 that drugmakers have no legal duty to develop safer alternatives to existing safe medications, siding with Gilead Sciences in a closely watched case. The decision dismissed negligence claims from approximately 24,000 patients using Gilead's HIV drug. Patients argued the company should have developed an alternative with fewer side effects more than 20 years ago. Justice Joshua Groban wrote that imposing a "duty to innovate" would require juries to second-guess complex scientific judgements. He warned it could create substantial burdens and risk adverse consequences for pharmaceutical innovation and public health. The ruling reversed a February 2024 appeals court decision. Dozens of trade groups and major drugmakers, including Pfizer, Merck and Johnson & Johnson, supported Gilead's appeal. HIV drugs accounted for 70% of Gilead's $29.4 billion revenue last year.